Symbiotec Pharmalab IPO GMP

Symbiotec Pharmalab IPO GMP Today

Symbiotec Pharmalab IPO   |   Mainboard IPO   |   BSE, NSE
Latest IPO GMP ₹295
Estimated Listing Price: ₹1,283
Expected Gain: 29.86%
Last updated: 21 August 2026
IPO Opens 24 Aug 2026
IPO Closes 27 Aug 2026
Listing Date 1 Sep 2026
Price Band ₹938 – ₹988
Total Issue Size ₹1,757 Cr
Latest GMP ₹295

Symbiotec Pharmalab IPO GMP Today, 21 August 2026

Symbiotec Pharmalab IPO GMP today is ₹295. The latest grey market premium is ₹295 as of 21 August 2026.

With the IPO upper price band fixed at ₹988 per share, the current GMP indicates an estimated listing price of ₹1,283 per share.

Based on the current GMP, the estimated gain is approximately 29.86% over the IPO upper price band.

The GMP is based on unofficial grey-market activity and may change before the listing date. Investors should not consider GMP as a guarantee of the actual listing price.

Symbiotec Pharmalab IPO Expected Listing Price

GMP-Based Listing Price Calculation

IPO Upper Price Band: ₹988

Upstox (Free Account Opening)

Flat ₹20 Per Trade.
Backed By Mr. Rata Tata

Latest GMP: ₹295

₹988 + ₹295 = ₹1,283

Therefore, the current GMP indicates an estimated listing price of ₹1,283 per share.

Estimated gain over the upper price band: 29.86%

Symbiotec Pharmalab IPO GMP Trend

Symbiotec Pharmalab IPO GMP is currently reported at ₹295 as of 21 August 2026.

The IPO is scheduled to open for subscription on 24 August 2026. GMP may change during the subscription period depending on market sentiment and demand.

GMP Date IPO Price GMP Estimated Listing Estimated Gain Last Updated
21-Aug-2026
Latest
₹988 ₹295 ▲ ₹1,283 29.86% 21-Aug-2026

* Estimated listing price is calculated using the IPO upper price band plus the latest GMP. GMP-based listing estimates are indicative and may differ from the actual listing price.

Symbiotec Pharmalab IPO Details

IPO Name Symbiotec Pharmalab IPO
Company Symbiotec Pharmalab Ltd.
Sector Pharmaceuticals, APIs & Biotechnology
IPO Type Mainboard
Issue Type Book Building Issue
Exchange BSE, NSE
Open Date 24 August 2026
Close Date 27 August 2026
Allotment Date 28 August 2026
Listing Date 1 September 2026
Price Band ₹938 – ₹988 per share
Face Value ₹2 per share
Lot Size 15 Shares
Minimum Investment ₹14,820
Total Issue Size ₹1,757 crore
Fresh Issue ₹150 crore
Offer for Sale ₹1,607 crore
Latest GMP ₹295
Estimated Listing Price ₹1,283
Estimated Gain 29.86%
Last GMP Update 21 August 2026

Symbiotec Pharmalab IPO GMP Profit Estimate

Based on the current GMP of ₹295 and the upper IPO price band of ₹988, the estimated listing price is ₹1,283.

Particular Calculation Amount
IPO Investment ₹988 × 15 Shares ₹14,820
Estimated Listing Value ₹1,283 × 15 Shares ₹19,245
Estimated Gain ₹19,245 − ₹14,820 ₹4,425

If the GMP remains at ₹295 until listing, one lot of 15 shares could indicate an estimated gain of approximately ₹4,425.

Symbiotec Pharmalab IPO GMP Update

Latest GMP

GMP Date: 21 August 2026

Latest GMP: ₹295

Current GMP = ₹295

The latest reported grey-market premium is ₹295 per share. Previous GMP data has not been included here unless separately reported.

What Is Symbiotec Pharmalab IPO GMP?

IPO GMP stands for Initial Public Offering Grey Market Premium. It represents the premium at which an IPO may be informally traded in the grey market before its official stock-market listing.

A positive GMP may indicate positive market sentiment toward the IPO, while a negative GMP may indicate expectations of a discounted listing.

However, the grey market is unofficial and unregulated. GMP can change significantly before the listing date and should not be treated as a guaranteed listing price.

Estimated Listing Price = IPO Upper Price Band + Latest GMP

₹988 + ₹295 = ₹1,283

Estimated Gain = (₹295 ÷ ₹988) × 100 = 29.86%
Disclaimer:

IPO GMP is based on unofficial grey-market indications and is provided for informational purposes only. GMP can change rapidly and does not guarantee the actual listing price or returns. The estimated listing price and gain shown above are calculated using the IPO upper price band and the reported GMP. Investors should conduct their own research and due diligence before making any investment decision.